Sibylla Biotech

# High-Level Overview

Sibylla Biotech is an early-stage biotechnology company, not a technology company in the traditional sense. Founded in 2017 and headquartered in Milan, Italy[2], Sibylla is a preclinical-stage drug discovery firm focused on developing small molecule protein degraders targeting oncological diseases[3]. The company's mission is to identify therapeutics against "undruggable" targets—proteins that have historically resisted conventional drug development approaches[1].

Sibylla serves the pharmaceutical and biotech industry by solving a critical problem: many disease-relevant proteins cannot be targeted with traditional small molecule drugs because they lack suitable binding pockets in their native, fully-folded state. The company addresses this by targeting proteins during their folding process, when they exist in intermediate conformations that are more amenable to drug binding[1]. Its lead candidate targets Cyclin D1, a protein implicated in various cancers[1], with additional pipeline focus on oncology targets like KRAS[4].

Core Differentiators

Sibylla's competitive advantages center on its proprietary platform technology:

• Protein Folding Interference (PPI-FIT) Platform: The company leverages a unique computational platform that models the vectorial nature of protein folding and nascent chain interactions with the ribosome[1]. This enables rational design of small molecules that induce target degradation by interfering with the folding process itself[1].

• Interdisciplinary Founding Team: Sibylla was founded by a physicist and biologist who pooled expertise across biotechnology, biology, and quantum physics[4]—an unusual combination that enabled the discovery of this novel therapeutic modality.

• Access to Capital: The company raised €23 million ($25 million) in Series A funding in October 2022, representing one of Italy's largest biotech financing rounds to date[4].

• Board-Level Expertise: Sibylla recently appointed an experienced Non-Executive Chair with global industry networks and multiple board positions at established biotech firms[2], signaling preparation for clinical advancement.

Role in the Broader Biotech Landscape

Sibylla operates at the intersection of two major biotech trends: the growing focus on protein degradation as a therapeutic modality and the application of computational biology and physics-based approaches to drug discovery. The company's timing is advantageous—protein degradation has emerged as a validated therapeutic strategy (evidenced by FDA-approved PROTAC drugs), yet most approaches target proteins in their native state. Sibylla's folding-interference approach opens an entirely new design space for undruggable targets, potentially expanding the addressable market for small molecule therapeutics.

The company influences the broader ecosystem by demonstrating that European biotech can pioneer cutting-edge therapeutic modalities and attract significant capital, while also validating the value of cross-disciplinary scientific teams in solving intractable drug discovery problems.

Quick Take & Future Outlook

Sibylla is positioned at a critical inflection point. With Series A funding secured and a Non-Executive Chair appointed, the company is preparing to advance its lead Cyclin D1 degrader into preclinical development and toward clinical trials[2]. Success here would validate the PPI-FIT platform and likely unlock additional funding for pipeline expansion.

The key question ahead is whether folding-interference degraders can achieve the same clinical efficacy and safety profile as other protein degradation approaches. If they do, Sibylla could establish a new standard for targeting previously undruggable oncology proteins—a market opportunity that extends far beyond its current pipeline. The company's ability to attract world-class board talent suggests investor confidence in this thesis, but clinical validation remains the ultimate test.